News & Publications

2012 CIC Roundtable: Benefit/Risk of Immunotherapy

During the CRI Cancer Immunotherapy Consortium Annual Colloquium in National Harbor, MD, a panel of immunologists and oncologists spoke on the benefits and risks of immunotherapy. Pictured here are: (top, L to R) James L. Gully, M.D., Ph.D., F.A.C.P ., National Institutes of Health; Axel Hoos, M.D., Ph.D., GlaxoSmithKline; Jill O'Donnell-Tormey, Ph.D., CRI; James P. Allison, Ph.D., MD Anderson Cancer Center; Larry Norton, M.D., MSKCC; Jedd D. Wolchok, M.D., Ph.D., MSKCC and Ludwig Institute for Cancer Research; Susan F. Slovin, M.D., Ph.D., MSKCC; Vincent G. Brichard, M.D., Ph.D., GlaxoSmithKline; and Philip Kantoff, M.D., Dana-Farber Cancer Institute.